Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114881 · ClinicalTrials.gov registry record
Urban Environmental Factors and Childhood Asthma
A clinical trial of Asthma and Allergy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 560
- Enrollment target
- 4
- Study locations
NCT00114881: Completed study of Asthma and Allergy, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00114881 is a study of Asthma and Allergy that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 560 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114881, a study of Asthma and Allergy, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 560 participants
- Enrollment target
- 4
- Study locations
Study Summary
Minority children who grow up in poor urban neighborhoods have the highest rates of asthma, and also experience greater morbidity from acute exacerbations of this disease. The aim of this study is to further identify environmental factors unique to the inner city that affect immune development and the expression of wheezing, atopy and asthma for purposes of identifying new strategies for asthma prevention.
Primary Outcome
Establish in inner city children the immunologic causes for the development of recurrent wheezing.
Study Locations (4)
Maryland
- Pediatric Clinical Research Unit, Johns Hopkins University - Baltimore
Massachusetts
- Boston Medical Center - Boston
Missouri
- Saint Louis Children's Hospital - St Louis
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2005-02-02 |
| Est. Completion | 2024-08-31 |
What the finished NCT00114881 record still lists
NCT00114881 is an observational study that tracks outcomes without assigning an intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT00114881 reports a single indexed study location in Maryland, Massachusetts, Missouri.
Frequently Asked Questions
What is clinical trial NCT00114881 about?
NCT00114881 is a clinical study titled "Urban Environmental Factors and Childhood Asthma". Minority children who grow up in poor urban neighborhoods have the highest rates of asthma, and also experience greater morbidity from acute exacerbations of this disease. The aim of this study is to further identify environmental factors unique to the inner city that affect immune development and t...
What is the current status of trial NCT00114881?
This trial is currently completed. The enrollment target is 560 participants. The study started on 2005-02-02. Estimated completion is 2024-08-31.
What conditions does trial NCT00114881 study?
This clinical trial studies the following conditions: Asthma, Allergy.
Who is sponsoring clinical trial NCT00114881?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114881 being conducted?
This trial has 4 study locations across Maryland, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00114881's enrollment target sits among peer trials
560 72nd of 374 higher than 303 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI